Your cart is currently empty!
Survodutide
$165.00
What is Survodutide? Survodutide is an investigational dual agonist targeting both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). Developed by Boehringer Ingelheim and Zealand Pharma, it has been studied in preclinical and early clinical models for its potential effects on metabolic regulation, including energy balance and body weight modulation. Research has focused on its relevance to obesity and metabolic dysfunction-associated steatohepatitis (MASH), with ongoing studies exploring its mechanisms of action and therapeutic potential. For Research Use Only. Not intended for human consumption, medical, diagnostic, or therapeutic purposes.
Description
| Chemical Formula | C225H347N47O68 |
| Molecular Mass | ~4751 Da |
| CAS Number | 2381089-83-2 |
| Form | Lyophilized peptide powder |
| Shelf Life | 24 months (lyophilized) |
| Intended Use | For preclinical and in vitro research only |
| Storage | −20 °C (dry powder), −80 °C (after reconstitution) |
In experimental research environments, survodutide is employed as a dual GLP-1 and glucagon receptor agonist to investigate coordinated incretin and glucagon signaling effects on metabolic pathways. Its dual-receptor activity enables the study of receptor balance, signaling interplay, and downstream metabolic responses under controlled laboratory conditions.
Preclinical investigations commonly utilize survodutide to examine energy utilization, metabolic flexibility, and adaptive signaling mechanisms associated with combined receptor activation. These studies contribute to comparative research efforts aimed at understanding differences between single-, dual-, and multi-receptor agonist strategies in metabolic research models.
Intended for laboratory research use only. Not for human or animal consumption, medical diagnosis, or therapeutic application.
Additional information
| Volume | 10MG |
|---|
Description
| Chemical Formula | C225H347N47O68 |
| Molecular Mass | ~4751 Da |
| CAS Number | 2381089-83-2 |
| Form | Lyophilized peptide powder |
| Shelf Life | 24 months (lyophilized) |
| Intended Use | For preclinical and in vitro research only |
| Storage | −20 °C (dry powder), −80 °C (after reconstitution) |
In experimental research environments, survodutide is employed as a dual GLP-1 and glucagon receptor agonist to investigate coordinated incretin and glucagon signaling effects on metabolic pathways. Its dual-receptor activity enables the study of receptor balance, signaling interplay, and downstream metabolic responses under controlled laboratory conditions.
Preclinical investigations commonly utilize survodutide to examine energy utilization, metabolic flexibility, and adaptive signaling mechanisms associated with combined receptor activation. These studies contribute to comparative research efforts aimed at understanding differences between single-, dual-, and multi-receptor agonist strategies in metabolic research models.
Intended for laboratory research use only. Not for human or animal consumption, medical diagnosis, or therapeutic application.
Additional information
| Volume | 10MG |
|---|
Reviews
There are no reviews yet.
Related products
-
Cagrilintide
$90.00 -
MOTS-C
$40.00 -
Retatrutide
Price range: $50.00 through $1,000.00 -
Semaglutide
Price range: $21.00 through $50.00 -
SLU-PP 332
$60.00
Reviews
There are no reviews yet.